Evidence map›Paper›PMID 32650495›Full record

ArticleCancers2020

Mambalgin-2 Induces Cell Cycle Arrest and Apoptosis in Glioma Cells via Interaction with ASIC1a.

Maxim Bychkov, Mikhail Shulepko, Dmitry Osmakov, Yaroslav Andreev, Anastasia Sudarikova, Valeria Vasileva, Marat S Pavlyukov, Yaroslav A Latyshev, Alexander A Potapov, Mikhail Kirpichnikov and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Therapeutic Promise and Biotechnological Prospects ofInternational journal of molecular sciences · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Ion Channel Involvement in Tumor Drug Resistance.Journal of personalized medicine · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Maxim BychkovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.
Mikhail ShulepkoShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.
Dmitry OsmakovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.ORCID 0000-0001-6588-5012
Yaroslav AndreevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.ORCID 0000-0002-7628-0980
Anastasia SudarikovaInstitute of Cytology, Russian Academy of Science, 194064 St-Petersburg, Russia.ORCID 0000-0003-0137-471X
Valeria VasilevaInstitute of Cytology, Russian Academy of Science, 194064 St-Petersburg, Russia.
Marat S PavlyukovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.
Yaroslav A LatyshevFederal State Autonomous Institution, N.N. Burdenko National Medical Research Center of Neurosurgery, 125047 Moscow, Russia.
Alexander A PotapovFederal State Autonomous Institution, N.N. Burdenko National Medical Research Center of Neurosurgery, 125047 Moscow, Russia.
Mikhail KirpichnikovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.
Zakhar O ShenkarevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.ORCID 0000-0003-1383-3522
Ekaterina LyukmanovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.
Institute of Bioorganic Chemistry · RUBurdenko Neurosurgery Institute · RUInstitute of Cytology · RUMoscow Institute of Physics and Technology · RUSechenov University · RULomonosov Moscow State University · RU

Funding

Council on grants of the President of the Russian Federation sp-4316.2018.4Program of Presidium of the Russian Academy of Sciences Molecular and Cell BiologyRussian Foundation for Basic Research 18-29-01050Russian Foundation for Basic Research 18-34-00497
6 · The paper itself

Abstract

Gliomas are fast growing and highly invasive brain tumors, characterized by tumor microenvironment acidification that drives glioma cell growth and migration. Channels containing Acid-sensing Ion Channel 1a subunit (ASIC1a) mediate amiloride-sensitive cation influx in late stage glioma cells, but not in normal astrocytes. Thus, selective targeting of ASIC1a can be a perspective strategy for glioma treatment. Here, ASIC1a expression in U251 MG and A172 glioma cells, but not in normal astrocytes, was demonstrated. Recombinant analog of mambalgin-2 from black mamba

Indexed as

amiloride-sensitive ion channelsapoptosisASICastrocytescell cycleglioblastomaLy6/uPARmambalgin-2three-finger proteins

Identifiers

PMID32650495
PMCPMC7408772
OpenAlexW3041701498

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.